Overview

Novel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple Myeloma

Status:
Not yet recruiting

Trial end date:
2023-08-01

Target enrollment:

Participant gender:

Summary

The purpose of this research study is to determine if two drugs approved for treating multiple myeloma, belantamab mafodotin and elotuzumab, are safe and more effective when used together.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Yale University

Collaborator:

GlaxoSmithKline, LLC

Treatments:

Elotuzumab